CUPERTINO, Calif., Nov. 11 /PRNewswire-FirstCall/ —
DURECT Corporation (Nasdaq: DRRX) announced today that it will postpone its
third quarter financial results press release and conference call to Tuesday,
November 12th, 2002.
The earnings release is postponed due to the announcement today by DURECT
Corporation and Endo Pharmaceuticals relating to the agreement to collaborate
on the development and commercialization of DURECT’s CHRONOGESIC(TM)
(sufentanil) Pain Therapy System for the U.S. and Canada. Endo and DURECT
will conduct a joint conference call to discuss the agreement on Monday,
November 11th, 2002 at 5:00 p.m. EST.
You are invited to listen to DURECT’s rescheduled third quarter 2002
earnings conference call that will be broadcast live over the Internet on
Tuesday, November 12th, 2002 at 4:30 p.m. EST with Jim Brown, President and
Chief Executive Officer, Tom Schreck, Chief Financial Officer and
Felix Theeuwes, Chairman and Chief Scientific Officer. This call will be
webcast live through DURECT’s corporate website and available for 30 days
following the call. To access the webcast, please log on to the Investor
Relations site of www.www.durect.com. The domestic call-in number is
1-800-915-4836. The international call-in number is 1-973-317-5319. A
rebroadcast of the call will be available by phone for 24 hours beginning
approximately one hour after the close of the call and can be accessed at
1-800-428-6051 (passcode: 264664).
If you are unable to participate during the live webcast, the call will be
archived on DURECT’s website under Audio Archive in the “Investor Relations”
section.
DURECT Corporation (www.www.durect.com) is pioneering the development and
commercialization of pharmaceutical systems for the treatment of chronic
debilitating diseases and enabling biotechnology-based pharmaceutical
products. DURECT’s goal is to deliver the right drug to the right site in the
right amount at the right time. In November 2001, DURECT completed a pilot
phase III program for the CHRONOGESIC(TM) (sufentanil) Pain Therapy System, a
3-month product for the treatment of chronic pain. DURECT owns three
proprietary drug delivery platform technologies, including the SABER(TM)
Delivery System (a patented and versatile depot injectable useful for protein
delivery), the MICRODUR(TM) Biodegradable Microparticulates (microspheres
injectable system) and the DURIN(TM) Biodegradable Implant (drug-loaded
implant system).
NOTE:
CHRONOGESIC(TM) is a trademark of DURECT Corporation. SABER(TM),
MICRODUR(TM) and DURIN(TM) are trademarks of Southern BioSystems, Inc., a
wholly owned subsidiary of DURECT Corporation. Other trademarks referred to
belong to their respective owners.
The statements in this press release regarding DURECT’s products in
development and product development plans, are forward-looking statements
involving risks and uncertainties that can cause actual results to differ
materially from those in such forward-looking statements. Potential risks and
uncertainties include, but are not limited to, DURECT’s ability to research,
develop, manufacture and commercialize its products, obtain product and
manufacturing approvals from regulatory agencies, manage its growth and
expenses, finance its activities and operations, as well as marketplace
acceptance of DURECT’s products. Further information regarding these and other
risks is included in DURECT’s Annual Report on Form 10-K for the fiscal year
ended December 31, 2001 filed with the SEC on March 28, 2002, under the
heading “Factors that may affect future results,” and other periodic reports
filed with the SEC. CHRONOGESIC is under development by DURECT and has not
been submitted or approved for commercialization by the US Food and Drug
Administration or other health authorities.
SOURCE DURECT Corporation
/CONTACT: Schond L. Greenway, Senior Director, Investor Relations and
Strategic Planning of DURECT Corporation, +1-408-777-1417, or
schond.greenway@durect.com/
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, +1-888-776-6555 or +1-212-782-2840 /